Mother of 2 coping with rare disease Pottstown Mercury, PA - Esslinger has been in the hospital for as long as seven days and the bone marrow transplant should put her up for four weeks. ?He asks, ?Mommy, are you ...
Mom Can't Give Marrow For Son's Cancer; She Has Breast Cancer Newsradio 620, WI - Nov 24, 2008 That despite discovering in trying to save her son David with a bone marrow transplant, that she has cancer herself. Mary found out months ago that David, ...
Bone Marrow transplant leads to functional cure for HIV The Argosy.ca, Canada - Nov 20, 2008 ...protein door handle (called CCR5) which would normally allow the virus to enter the cell. When the American patient received a bone marrow transplant to ...
Doctors, researchers on quest for a cure News-Herald.com, OH - Nov 28, 2008 They can not only replace the bone marrow, they can fight off the tumor." The improvements in treatment and survivorship rates also have created a new ...
German AIDS cure good for 1% of patients NDTV.com, India - Nov 23, 2008 Attempts to use bone-marrow transplants in HIV/AIDS treatment have been made since the 1980s. In one case, a patient with both HIV/AIDS and lymphoma died of ...
Mortgagee sales on the increase New Zealand Herald, New Zealand - The proportion of sales listings that are mortgagee listings rose to 0.34 per cent from 0.32 per cent the previous week and 0.21 per cent when the survey ...
Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin - P Brunet, AM Lorec, F Leonetti, C Roubicek, K … - Nephrology Dialysis Transplantation, 1994 - ERA-EDTA ... r 0.34 0.94 0.39 0.68 0.50 0.59 0.13 0.27 0.66 mean BP ... Proc Natl Acad Sci USA 1988;
85: 9797-9800 P. Brunet et al. ... Nephrol Dial Transplant 1990; 5: 418-422 19. ...
A review of the epidemiological evidence for the ?antioxidant hypothesis? - SA Stanner, J Hughes, CNM Kelly, J Buttriss - Public Health Nutrition, 2007 - Cambridge Univ Press ... Vitamin E treatment significantly reduced the risk of CVD death and non-fatal MI
combined (relative risk (RR) 0.53, 95% confidence interval (CI) 0.34?0.83). ...
On glomerular structural alterations in type-1 diabetes - R ?sterby, HJ Bangstad, G Nyberg, S Rudberg - Virchows Archiv, 2001 - Springer ... Center, Oslo, Norway Gudrun Nyberg Transplant Unit, Sahlgrenska ... At a higher
magnification (9800?), a subsample of ... V (matrix) per glom 0.23 (33) 0.34 (36) 0.01 ...
Endothelin receptors in the human coronary artery, ventricle and atrium - WA Bax, AT Bruinvels, RJ Suylen, PR Saxena, D … - Naunyn-Schmiedeberg's Archives of Pharmacology, 1993 - Springer ... l'15]ET-I plCs0 high 9.59_+0.34 9.48-+0.16 ... hearts (dilating car- diomyopathy, obtained
from heart transplant recipients ... Proc Natl Acad Sci USA 85:9797-9800 Fan T ...
[CITATION] Avalia??o dos pacientes submetidos ? quantifica??o de c?lulas CD34 por citometria de fluxo R da Silva, SI Ferreira, AS Cordoba, P Haas - RBAC, 2003 -
Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. - BJ Epstein, K Vogel, BF Palmer - Drugs, 2007 - drugs.adisonline.com ... of end-stage renal disease (ESRD) or transplant (ACE inhibitors ... After 6 weeks of
diuretic therapy, 9800 patients were ... in each group (6.3% vs 5.8%; p = 0.34). ...
SATURDAY, Feb. 18 (HealthDay News) -- Measuring levels of a specific protein seven days after bone-marrow transplant helps predict which patients are likely to develop the serious and potentially deadly complication called graft vs. host disease (GVHD), researchers report.
The protein, called tumor necrosis factor (TNF), is known to be elevated in people who develop GVHD, which occurs when the transplanted bone marrow immune cells attack the patient's skin, liver and gastrointestinal cells, resulting in a massive inflammatory response that can cause death.
This University of Michigan study included 170 bone-marrow transplant patients, including 94 who developed GVHD. Bone-marrow transplants are typically given to children or adults with certain kinds of cancer -- such as leukemia or lymphoma -- or with some blood or immune disorders.
The researchers pointed out that the 94 patients had elevated TNF levels a week after their transplant, but before they showed any signs of GVHD.
They also found that patients with elevated TNF levels seven days after transplant had a 20 percent lower survival rate: just 62 percent of these patients were alive a year after their transplant, compared with 85 percent of patients with lower TNF levels.
"This suggests we could target patients to prevent graft vs. host disease based on their post-transplant level of TNF," study author Dr. John Levine, associate professor of pediatrics and internal medicine, said in a prepared statement. "If we can develop a test that can reliably predict this complication, we can look at treating it before any symptoms develop. This is one small step in a long road to making transplants safer and more effective."
The findings were presented Friday at the annual meeting of the American Society for Blood and Marrow Transplant in Honolulu.
